Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial - Luke, JJ; Rutkowski, P; Queirolo, P (Lancet, 2022)
et al.